The brief reply to which nations permit medical hashish is: greater than many individuals assume, however far fewer than headlines generally counsel. The longer reply is the place the actual story sits. In 2025, dozens of nations have some type of authorized medical hashish framework, but entry, prescribing guidelines, product classes and affected person eligibility differ so broadly that two authorized markets can look nothing alike.
For operators, buyers, policymakers and healthcare-adjacent readers, that distinction issues. A rustic could allow cannabis-based medicines with out permitting flower. One other could permit specialist prescribing however supply no home provide chain. A 3rd could have laws on paper whereas sufferers nonetheless face delays, patchy reimbursement or import bottlenecks. So the higher query is just not solely which nations permit medical hashish, however what they really permit in observe.
Which nations permit medical hashish in observe?
Throughout Europe, the Americas, components of Oceania, and chosen markets in Africa and Asia, medical hashish has moved from fringe coverage to regulated healthcare dialogue. That doesn’t imply full legalisation, and it doesn’t all the time imply a functioning business market.
Nations broadly recognised as permitting medical hashish in some kind embrace Germany, the UK, Italy, the Netherlands, Portugal, Denmark, Malta, Greece, Poland, Czechia, Switzerland beneath managed pathways, Eire, Australia, New Zealand, Israel, Thailand, Colombia, Uruguay, Peru, Brazil, Argentina, Chile, Mexico beneath evolving authorized circumstances, South Africa in restricted varieties, and a lot of US states. Canada additionally permits medical hashish nationally, though its adult-use framework usually attracts extra consideration.
That listing wants a caveat. In some jurisdictions, solely registered pharmaceutical hashish merchandise are permitted. In others, magistral preparations, oil extracts or dried flower can be found. Elsewhere, pilot schemes or ministerial approvals exist with out significant scale. Authorized standing and actual entry are usually not the identical factor.
Europe has authorized markets, however not a single mannequin
Europe is commonly handled as one medical hashish story. It isn’t. The area is best understood as a set of separate reimbursement programs, prescribing cultures and political danger profiles.
Germany stays probably the most commercially important medical market in Europe. Since broad reform in 2017, physicians have been capable of prescribe hashish for critical circumstances when different therapies are unsuitable. The market has expanded by means of imports, pharmacy meting out and a rising base of insured and self-paying sufferers. But Germany can be instance of why headline legality can mislead. Doctor warning, insurer scrutiny and administrative friction nonetheless form entry.
The UK permits specialist docs to prescribe cannabis-based merchandise for medicinal use, however affected person entry stays narrower than many anticipated after the 2018 reform. A small variety of NHS prescriptions have been issued, whereas most real-world entry has come by means of non-public clinics. For a market watcher, that makes the UK legally open however structurally constrained.
The Netherlands has one of many oldest established programs, centred on regulated medical provide by means of pharmacies. Italy additionally permits medical use, however entry can fluctuate by area and provide consistency has been a problem. Portugal has constructed a status as a manufacturing and export hub, although home affected person uptake has not all the time matched cultivation momentum.
Denmark’s medical hashish pilot programme, Poland’s prescription mannequin, Czechia’s reforms and Ireland’s limited access scheme all present the identical pattern: Europe is shifting, however inconsistently. The coverage route is mostly constructive, whereas the operational image nonetheless relies on native prescribing habits, product availability and reimbursement guidelines.
The Americas vary from mature programs to authorized gray zones
In North America, Canada presents the clearest nationwide framework. Medical hashish has been authorized for years, with licensed producers and established affected person pathways. As a result of adult-use hashish can be authorized, the medical channel now competes with a broader retail market. That creates an uncommon dynamic the place medical entry is authorized and mature, however business differentiation turns into extra necessary.
America is tougher to categorise in a single sentence. Federally, hashish stays unlawful, however a majority of states have medical cannabis programmes. For companies and observers, this creates a split-screen actuality: intensive affected person entry at state degree, paired with federal banking, analysis and interstate commerce boundaries. The US due to this fact belongs on any listing of locations that permit medical hashish, however solely with the understanding that it’s a state-driven system somewhat than a unified nationwide market.
In Latin America, Colombia has positioned itself as a critical regulatory and manufacturing participant, significantly round cultivation and extracts. Uruguay, higher identified for adult-use legalisation, additionally permits medical entry. Brazil has expanded affected person entry by means of imports and authorised cannabis-based merchandise, although the framework stays tightly managed. Argentina has progressively widened entry and home manufacturing channels. Mexico has seen repeated legal and regulatory movement, however implementation has been slower and fewer simple than reform advocates as soon as hoped.
For buyers and operators, Latin America nonetheless presents promise, although not each reform has translated into speedy income. Political shifts, court docket actions and bureaucratic lag can all have an effect on timing.
Asia-Pacific is rising, however cautiously
Australia has grow to be one of many extra lively medical hashish markets exterior Europe and North America. Its system has grown by means of authorised prescribing and particular entry pathways, and affected person numbers have risen sharply lately. The nation now issues not solely as a regulated market but additionally as a sign that mainstream healthcare programs can take up cannabinoid remedy inside a traditional compliance construction.
New Zealand permits medical hashish beneath a regulated scheme, although product availability and value have influenced uptake. Israel stays one of many sector’s most necessary markets as a result of its medical programme, analysis historical past and coverage affect, whilst its regulatory strategy continues to evolve.
Thailand attracted international consideration when it legalised medical hashish after which moved by means of a broader, extra politically contested hashish section. Its trajectory has been a reminder that coverage liberalisation is just not all the time linear. Asia-Pacific markets can transfer quick, however they will additionally reverse, tighten or reframe guidelines with restricted discover.
Why authorized doesn’t all the time imply accessible
That is the half many informal round-ups miss. A rustic can permit medical hashish and nonetheless depart sufferers with weak entry.
Typically the barrier is medical. Docs could also be permitted to prescribe, however reluctant to take action as a result of proof requirements, coaching gaps or skilled danger stay unresolved. Typically the barrier is monetary. Merchandise could also be authorized but costly, with little or no reimbursement. In different instances the issue is logistical, particularly in import-reliant markets the place inventory shortages can disrupt continuity of care.
There’s additionally a class drawback. Some nations permit cannabis-derived medicines authorised by means of conventional pharmaceutical routes, resembling particular cannabinoid formulations, however don’t allow broader natural hashish prescribing. That distinction is central for companies deciding whether or not they’re taking a look at a pharmaceutical market, a pharmacy-dispensed flower market, or a hybrid mannequin.
What companies and coverage watchers ought to observe subsequent
If the query is which nations permit medical hashish, the extra strategic follow-up is which of these nations are constructing sturdy markets. Three indicators matter most.
First is prescribing infrastructure. A authorized framework with out physician participation will keep small. Second is product structure – whether or not regulators allow solely oils and isolates or a wider vary together with flower and compounded merchandise. Third is payer behaviour. Reimbursement, even partial, can reshape market measurement way more rapidly than permissive laws alone.
Commerce guidelines and home cultivation coverage additionally deserve shut consideration. A number of nations have tried to stability affected person entry with native trade growth, and that may have an effect on licensing, imports and pricing. For multinational operators, these selections affect all the pieces from margins to market-entry timelines.
For readers following MEDCAN24 and the broader sector, the clearest pattern is that medical hashish is now not a distinct segment coverage experiment. It’s now a part of a broader healthcare, regulatory and business dialog throughout a number of areas. Nevertheless it stays fragmented. The nations shifting from symbolic legalisation to practical entry would be the ones that matter most over the following section of market growth.
That’s the reason the neatest solution to learn the map is to not ask solely the place medical hashish is authorized. Ask the place sufferers can realistically get hold of it, the place clinicians are prepared to prescribe it, and the place regulators are constructing a system that may nonetheless make sense 5 years from now.